These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
281 related articles for article (PubMed ID: 24566170)
1. A prospective evaluation of the predictive value of faecal calprotectin in quiescent Crohn's disease. Naismith GD; Smith LA; Barry SJ; Munro JI; Laird S; Rankin K; Morris AJ; Winter JW; Gaya DR J Crohns Colitis; 2014 Sep; 8(9):1022-9. PubMed ID: 24566170 [TBL] [Abstract][Full Text] [Related]
2. Usefulness of a rapid faecal calprotectin test to predict relapse in Crohn's disease patients on maintenance treatment with adalimumab. Ferreiro-Iglesias R; Barreiro-de Acosta M; Lorenzo-Gonzalez A; Dominguez-Muñoz JE Scand J Gastroenterol; 2016; 51(4):442-7. PubMed ID: 26595391 [TBL] [Abstract][Full Text] [Related]
3. Fecal calprotectin is a predictive marker of relapse in Crohn's disease involving the colon: a prospective study. Kallel L; Ayadi I; Matri S; Fekih M; Mahmoud NB; Feki M; Karoui S; Zouari B; Boubaker J; Kaabachi N; Filali A Eur J Gastroenterol Hepatol; 2010 Mar; 22(3):340-5. PubMed ID: 19581809 [TBL] [Abstract][Full Text] [Related]
4. Low fecal calprotectin predicts clinical remission in Crohn's disease patients: the simple answer to a challenging question. Monteiro S; Dias de Castro F; Leite S; Moreira MJ; Cotter J Scand J Gastroenterol; 2019 Jan; 54(1):49-54. PubMed ID: 30663515 [TBL] [Abstract][Full Text] [Related]
5. Measurement of fecal calprotectin improves monitoring and detection of recurrence of Crohn's disease after surgery. Wright EK; Kamm MA; De Cruz P; Hamilton AL; Ritchie KJ; Krejany EO; Leach S; Gorelik A; Liew D; Prideaux L; Lawrance IC; Andrews JM; Bampton PA; Jakobovits SL; Florin TH; Gibson PR; Debinski H; Macrae FA; Samuel D; Kronborg I; Radford-Smith G; Selby W; Johnston MJ; Woods R; Elliott PR; Bell SJ; Brown SJ; Connell WR; Day AS; Desmond PV; Gearry RB Gastroenterology; 2015 May; 148(5):938-947.e1. PubMed ID: 25620670 [TBL] [Abstract][Full Text] [Related]
6. Fecal Calprotectin as Predictor of Relapse in Patients With Inflammatory Bowel Disease Under Maintenance Infliximab Therapy. Ferreiro-Iglesias R; Barreiro-de Acosta M; Otero Santiago M; Lorenzo Gonzalez A; Alonso de la Peña C; Benitez Estevez AJ; Dominguez-Muñoz JE J Clin Gastroenterol; 2016 Feb; 50(2):147-51. PubMed ID: 25811118 [TBL] [Abstract][Full Text] [Related]
7. Fecal calprotectin is a strong predictive marker of relapse in Chinese patients with Crohn's disease: a two-year prospective study. Ye L; Chen BQ; Wang SD; Shi H; Yang Z; Wang FY Scand J Gastroenterol; 2017 Oct; 52(10):1113-1119. PubMed ID: 28675068 [TBL] [Abstract][Full Text] [Related]
8. Fecal calprotectin measurement is a marker of short-term clinical outcome and presence of mucosal healing in patients with inflammatory bowel disease. Kostas A; Siakavellas SI; Kosmidis C; Takou A; Nikou J; Maropoulos G; Vlachogiannakos J; Papatheodoridis GV; Papaconstantinou I; Bamias G World J Gastroenterol; 2017 Nov; 23(41):7387-7396. PubMed ID: 29151692 [TBL] [Abstract][Full Text] [Related]
9. Prediction of Crohn's disease relapse with faecal calprotectin in infliximab responders: a prospective study. Laharie D; Mesli S; El Hajbi F; Chabrun E; Chanteloup E; Capdepont M; Razaire S; de Lédinghen V; Zerbib F Aliment Pharmacol Ther; 2011 Aug; 34(4):462-9. PubMed ID: 21671970 [TBL] [Abstract][Full Text] [Related]
10. Raised faecal calprotectin is associated with subsequent symptomatic relapse, in children and adolescents with inflammatory bowel disease in clinical remission. Diederen K; Hoekman DR; Leek A; Wolters VM; Hummel TZ; de Meij TG; Koot BG; Tabbers MM; Benninga MA; Kindermann A Aliment Pharmacol Ther; 2017 Apr; 45(7):951-960. PubMed ID: 28138990 [TBL] [Abstract][Full Text] [Related]
11. A prospective single-centre evaluation of the intra-individual variability of faecal calprotectin in quiescent Crohn's disease. Naismith GD; Smith LA; Barry SJ; Munro JI; Laird S; Rankin K; Morris AJ; Winter JW; Gaya DR Aliment Pharmacol Ther; 2013 Mar; 37(6):613-21. PubMed ID: 23347334 [TBL] [Abstract][Full Text] [Related]
12. Accuracy of Consecutive Fecal Calprotectin Measurements to Predict Relapse in Inflammatory Bowel Disease Patients Under Maintenance With Anti-TNF Therapy: A Prospective Longitudinal Cohort Study. Ferreiro-Iglesias R; Barreiro-de Acosta M; Lorenzo-Gonzalez A; Dominguez-Muñoz JE J Clin Gastroenterol; 2018 Mar; 52(3):229-234. PubMed ID: 27984399 [TBL] [Abstract][Full Text] [Related]
13. Fecal calprotectin: a selection tool for small bowel capsule endoscopy in suspected IBD with prior negative bi-directional endoscopy. Koulaouzidis A; Douglas S; Rogers MA; Arnott ID; Plevris JN Scand J Gastroenterol; 2011 May; 46(5):561-6. PubMed ID: 21269246 [TBL] [Abstract][Full Text] [Related]
14. Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn's disease. Costa F; Mumolo MG; Ceccarelli L; Bellini M; Romano MR; Sterpi C; Ricchiuti A; Marchi S; Bottai M Gut; 2005 Mar; 54(3):364-8. PubMed ID: 15710984 [TBL] [Abstract][Full Text] [Related]
15. Role of fecal calprotectin testing to predict relapse in teenagers with inflammatory bowel disease who report full disease control. van Rheenen PF Inflamm Bowel Dis; 2012 Nov; 18(11):2018-25. PubMed ID: 22275341 [TBL] [Abstract][Full Text] [Related]
16. Fecal Calprotectin in Ileal Crohn's Disease: Relationship with Magnetic Resonance Enterography and a Pathology Score. Cerrillo E; Beltrán B; Pous S; Echarri A; Gallego JC; Iborra M; Pamies J; Nos P Inflamm Bowel Dis; 2015 Jul; 21(7):1572-9. PubMed ID: 26052967 [TBL] [Abstract][Full Text] [Related]